Margot Vattaire-Hervé

Margot Vattaire-Hervé

Auto-generated profile, based on publicly available information

Margot Vattaire-Hervé

Jean Godinot Institute

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
MVMargot Vattaire-Hervé
Margot Vattaire-Hervé
ABAntoine Le Bozec
Antoine Le Bozec
JCJustine Clarenne
Justine Clarenne
GCGuillaume Cohet
Guillaume Cohet
VLViolaine Lepage
Violaine Lepage
FSFlorian Slimano
Florian Slimano
Purpose: The high-dose methotrexate (HD-MTX) regimen (>1 g/m 2 ) is the standard of care for preventing and managing central nervous system (CNS) invasion in diffuse large B-cell lymphoma (DLBCL). Delayed elimination of HD-MTX can lead to severe toxicity. Albumin is a suggested biological marker to predict delayed elimination. This study aims to evaluate whether serum albumin can be used as a predictive factor. Methods: This retrospective bicentric study includes DLBCL patients, receiving HD-MTX from 06.30.2016 to 12.31.2023 using CHIMI0v5.9. Data collected included demographic, biological, clinical and therapeutic. Eligible patients were over 18 years, with DLBCL diagnosis, available serum albumin before HD-MTX, with therapeutic drug monitoring of plasma methotrexate available. Univariate and multivariate analysis compared patients with and without delayed elimination. Results: A total of 68 patients were included, with 15 suffering delayed elimination. Univariate analysis showed that male and Body Surface Area ≥ 2 m² (BSA) patients were more likely to have delayed clearance (respectively p = 0.01; p = 0.05). The association with male sex was confirmed in multivariate analysis (p = 0.01). Most cases of hypoalbuminemia were classified as grade 1 or 2. Patients with hypoalbuminemia received lower doses of MTX. Serum albumin level was not significantly associated with delayed elimination (p = 0.8). Conclusions: Overall, mainly biometric factors are associated with delayed elimination, highlighting the problem of prescribing habits based on body surface area. Albuminemia's role remains debated, and this study does not provide a conclusion, as patients with hypoalbuminemia received lower HD-MTX doses. Studies should account factors related to inflammation, nutrition and specific biomarkers (prealbumin).

9 October 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
MVMargot Vattaire-Hervé
Margot Vattaire-Hervé
CBCoralie Barbe
Coralie Barbe
LBLeïla Bouazzi
Leïla Bouazzi
DPDamien Parent
Damien Parent
Introduction: Immune checkpoint inhibitors (ICI) are widely used in oncology. By stimulating immunity, their mechanism induces immune-related adverse events (irAE). Some studies suggest that certain drugs may exacerbate these toxicities (dysbiosis). This study aims to assess the link between taking chronic medications and the occurrence of immune-related adverse event during ICI treatment. Methods: This retrospective monocentric study includes adult patients who started an ICI treatment between 06.01.23 and 12.31.23. Clinical characteristics were extracted from medical records. The use of chronic medicines during ICI treatment was screened. The occurrence of an IRAE within 12 months following ICI initiation was monitored. Results: A total of 76 patients were included, mainly treated with pembrolizumab (88%). Fifty-four patients (71%) suffered from at least one irAE within one year (41% endocrine, 37% hepatic and 20% dermatological). PPI were the most prescribed chronic drug (33%). Taking chronic treatments was not associated with the occurrence of an IRAE (p = 0.19). Toxicity's severity was not significantly associated with having chronic medication (p = 0.43). No association was found between PPI or NSAID use and digestive toxicity (respectively p = 0.29;p = 0.99). Breast cancer treatment was significantly associated with irAE occurrence (p = 0.02). Conclusion: In this cohort, irAE were highly prevalent. Pembrolizumab-treated patients were predominant and chronic co-medications were not associated with the occurrence of irAE. However, the design of the study, short follow-up and limited sample size may have limited the detection of an effect. In order to anticipate irAE consequences, larger prospective studies are needed to clarify the role of co-medications in their occurrence.